Stock Information

In this section you will find detailed information regarding the Evotec SE share, such as basic share data over share price summary, stock price and charts, shareholder structure, our financial analysts and their latest recommendations, and our dividend policy.

Basic Share Data

Listing on NASDAQ

Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO).

Please find all further information regarding the NASDAQ listing as well as all published filings of Evotec SE here.

Stock Price & Chart

Shareholder Structure

On 31 March 2024, the number of total voting rights amounts to 177,542,097.

Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found here.

Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 73% according to our estimates (Evotec: 03|2024).

Shareholder structure (in %)*

Shareholder Structure

Rounding differences may occur.


Overview of analysts covering the Evotec share.

Bank Of America Analyst Logo

Bank of America

Derik de Bruin

Latest update: April 2024

BofA Securities

NYI-100-16-03 One Bryant Park
New York, NY 10036
United States Of America

Bryan, Garnier & Co Analyst Logo

Bryan Garnier & Co

Alex Cogut

Latest update: April 2024

92 Avenue des Champs-Elysées
Paris 75008

Citi Analyst Logo

Citigroup Inc.

Peter Verdult

Latest update: April 2024

One Court Square, 45th Floor
Long Island City, New York 11120
United States of America

TD Cowen Analyst Logo

TD Cowen

Steven Mah

Latest update: April 2024

Two International Place
Boston, MA 02110
United States Of America

Deutsche Bank Analyst Logo

Deutsche Bank

Falko Friedrichs

Latest update: April 2024

Große Gallusstraße 10-14
Frankfurt am Main 60311



Thomas Schiessle

Latest update: April 2024

AM Schieferstein 1
Frankfurt am Main 60435

H.C. Wainwright & Co Analyst Logo

H.C. Wainwright & Co.

Douglas Tsao

Latest update: April 2024

430 Park Ave., 4th Floor
New York, New York, 1002
United States of America

Intron Health Analyst Logo

Intron Health

Naresh Chouhan

Latest update: April 2024

New Street Research LLP
11 Austin Friars
London EC2N 2HG
United Kingdom

Jefferies Analyst Logo


Ben Jackson

Latest update: April 2024

100 Bishopsgate 
London EC2N 4JL
United Kingdom

Morgan Stanley Analyst Logo

Morgan Stanley

James Quigley

Latest update: April 2024

Morgan Stanley & Co. LLC
1585 Broadway Avenue
New York, NY 10036
United States of America

ODDO BHF Analyst Logo


Stephan Wulf

Latest update: April 2024

Bockenheimer Landstraße 10
Frankfurt am Main 60323

RBC Analyst Logo

Royal Bank of Canada (RBC)

Charles Weston

Latest update: April 2024

Royal Bank of Canada Europe Ltd.,

100 Bishopsgate
London, EC2N 4AA,
United Kingdon

Rx Securities Analyst Logo

Rx Securities

Dr Samir Devani

Latest update: April 2024

1 Fore Street, Moorgate, Third Floor
London EC2Y 9DT
United Kingdom

Van Lonschot Kempen Analyst Logo

Van Lanschot Kempen

Sebastiaan van der Schoot

Latest update: April 2024

Beethovenstraat 300
Amsterdam 1077 WZ

M.M. Warburg And Co Analyst Logo

Warburg Research

Dr Christian Ehmann

Latest update: April 2024

Ferdinandstraße 75
Hamburg 20095

Latest Analyst Recommendations

Below you will find the latest analyst recommendations.

Important Notice:

Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list.

Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements, Evotec is not allowed to publish the analyst reports.

Evotec's Dividend Policy

The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements.

Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage long-term growth and sustainability.

Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward.

All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares.

Contact Us

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.